ES2659264T3 - Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS - Google Patents
Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS Download PDFInfo
- Publication number
- ES2659264T3 ES2659264T3 ES12824342.5T ES12824342T ES2659264T3 ES 2659264 T3 ES2659264 T3 ES 2659264T3 ES 12824342 T ES12824342 T ES 12824342T ES 2659264 T3 ES2659264 T3 ES 2659264T3
- Authority
- ES
- Spain
- Prior art keywords
- patients
- colorectal cancer
- mutation
- patient
- tas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011177838 | 2011-08-16 | ||
| JP2011177838 | 2011-08-16 | ||
| PCT/JP2012/070745 WO2013024865A1 (ja) | 2011-08-16 | 2012-08-15 | Kras遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2659264T3 true ES2659264T3 (es) | 2018-03-14 |
Family
ID=47715182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12824342.5T Active ES2659264T3 (es) | 2011-08-16 | 2012-08-15 | Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9371380B2 (enExample) |
| EP (1) | EP2746404B1 (enExample) |
| JP (1) | JP5832541B2 (enExample) |
| KR (1) | KR101693090B1 (enExample) |
| CN (1) | CN103764847B (enExample) |
| AU (1) | AU2012295841B2 (enExample) |
| CY (1) | CY1119869T1 (enExample) |
| DK (1) | DK2746404T3 (enExample) |
| ES (1) | ES2659264T3 (enExample) |
| HR (1) | HRP20180130T1 (enExample) |
| HU (1) | HUE035347T2 (enExample) |
| LT (1) | LT2746404T (enExample) |
| NO (1) | NO2746404T3 (enExample) |
| PL (1) | PL2746404T3 (enExample) |
| PT (1) | PT2746404T (enExample) |
| RS (1) | RS56911B1 (enExample) |
| RU (1) | RU2585528C2 (enExample) |
| SI (1) | SI2746404T1 (enExample) |
| SM (1) | SMT201800108T1 (enExample) |
| TW (1) | TWI550089B (enExample) |
| WO (1) | WO2013024865A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2998742A4 (en) * | 2013-05-17 | 2017-01-18 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| UA123403C2 (uk) * | 2016-02-05 | 2021-03-31 | Тайхо Фармасьютікал Ко., Лтд. | Спосіб лікування хворих на рак з тяжкою нирковою недостатністю |
| AU2017397458B2 (en) * | 2017-02-01 | 2025-07-10 | Modernatx, Inc. | RNA cancer vaccines |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1849470T5 (pl) | 2005-01-26 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
-
2012
- 2012-08-15 KR KR1020147006642A patent/KR101693090B1/ko active Active
- 2012-08-15 PL PL12824342T patent/PL2746404T3/pl unknown
- 2012-08-15 EP EP12824342.5A patent/EP2746404B1/en active Active
- 2012-08-15 CN CN201280040055.4A patent/CN103764847B/zh active Active
- 2012-08-15 JP JP2013529023A patent/JP5832541B2/ja active Active
- 2012-08-15 DK DK12824342.5T patent/DK2746404T3/en active
- 2012-08-15 SM SM20180108T patent/SMT201800108T1/it unknown
- 2012-08-15 US US14/238,569 patent/US9371380B2/en active Active
- 2012-08-15 LT LTEP12824342.5T patent/LT2746404T/lt unknown
- 2012-08-15 AU AU2012295841A patent/AU2012295841B2/en active Active
- 2012-08-15 WO PCT/JP2012/070745 patent/WO2013024865A1/ja not_active Ceased
- 2012-08-15 NO NO12824342A patent/NO2746404T3/no unknown
- 2012-08-15 SI SI201231194T patent/SI2746404T1/en unknown
- 2012-08-15 HR HRP20180130TT patent/HRP20180130T1/hr unknown
- 2012-08-15 ES ES12824342.5T patent/ES2659264T3/es active Active
- 2012-08-15 RU RU2014109999/10A patent/RU2585528C2/ru active
- 2012-08-15 HU HUE12824342A patent/HUE035347T2/en unknown
- 2012-08-15 RS RS20180124A patent/RS56911B1/sr unknown
- 2012-08-15 PT PT128243425T patent/PT2746404T/pt unknown
- 2012-08-16 TW TW101129724A patent/TWI550089B/zh active
-
2018
- 2018-01-31 CY CY20181100119T patent/CY1119869T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2013024865A1 (ja) | 2015-03-05 |
| JP5832541B2 (ja) | 2015-12-16 |
| NO2746404T3 (enExample) | 2018-05-05 |
| TW201319257A (zh) | 2013-05-16 |
| WO2013024865A1 (ja) | 2013-02-21 |
| RU2585528C2 (ru) | 2016-05-27 |
| TWI550089B (zh) | 2016-09-21 |
| EP2746404B1 (en) | 2017-12-06 |
| EP2746404A1 (en) | 2014-06-25 |
| SMT201800108T1 (it) | 2018-05-02 |
| RU2014109999A (ru) | 2015-10-10 |
| SI2746404T1 (en) | 2018-04-30 |
| DK2746404T3 (en) | 2018-01-15 |
| CY1119869T1 (el) | 2018-06-27 |
| HK1197086A1 (zh) | 2015-01-02 |
| HRP20180130T1 (hr) | 2018-04-06 |
| CN103764847B (zh) | 2016-05-11 |
| HUE035347T2 (en) | 2018-05-02 |
| PT2746404T (pt) | 2018-01-10 |
| PL2746404T3 (pl) | 2018-04-30 |
| CN103764847A (zh) | 2014-04-30 |
| KR20140057328A (ko) | 2014-05-12 |
| AU2012295841B2 (en) | 2015-12-10 |
| RS56911B1 (sr) | 2018-05-31 |
| EP2746404A4 (en) | 2015-04-08 |
| US9371380B2 (en) | 2016-06-21 |
| AU2012295841A1 (en) | 2014-04-03 |
| LT2746404T (lt) | 2018-04-25 |
| US20140213602A1 (en) | 2014-07-31 |
| KR101693090B1 (ko) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silvera et al. | Translational control in cancer | |
| JP6193268B2 (ja) | Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| JP2023512039A (ja) | 化合物及びその使用 | |
| ES2659264T3 (es) | Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS | |
| ES2953005T3 (es) | Tratamiento para el cáncer | |
| ES2968789T3 (es) | Procedimiento combinado para el tratamiento del cáncer | |
| JP6823587B2 (ja) | Mdm2阻害剤とbtk阻害剤との併用治療法 | |
| US20210214390A1 (en) | Rapaglutins, novel inhibitors of glut and use thereof | |
| BR112020008537A2 (pt) | inibidores duplos de vias da tim-3 e da pd-1 | |
| JP2023512181A (ja) | 癌を治療するためのegfr阻害剤とror1阻害剤の組み合わせ | |
| US20120156310A1 (en) | Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure | |
| WO2025075211A1 (en) | Alisertib and paclitaxel for treating small cell lung cancer | |
| ES2362115T3 (es) | Composición farmacéutica para su uso en el tratamiento de individuos que presentan proteína kit mutante. | |
| Duffy et al. | Kinase Inhibition for Immuno-oncology | |
| HK1197086B (en) | Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer | |
| Govind Babu et al. | Adjuvant and Neoadjuvant | |
| JPWO2010074240A1 (ja) | 化学療法の治療効果予測方法 | |
| Fiebig et al. | 282 POSTER 5-Methyl-indirubin: a CDK-inhibitor with activity in human tumor models in vivo | |
| Camidge et al. | 281 POSTER A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results | |
| Ducommun et al. | 280 POSTER Targeting CDC25 phosphatases in cancer therapy | |
| Bhattacharya et al. | 251 ORAL The phosphatidylinositide 3-kinase (P13-kinase) inhibitor Pl103 sensitises some ovarian carcinoma (OC) cell lines to paclitaxel or carboplatin | |
| WO2010074241A1 (ja) | 併用化学療法の治療効果予測方法 |